Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health Inc. has demonstrated a strong commitment to growth, as evidenced by the anticipated sequential EBITDA improvements of $10-15 million for the third and fourth quarters, projecting $32.5 million for Q3 and $45 million for Q4. The company supports its positive outlook with a legacy Performance Suite MER expected to improve by 500 basis points to 89%, alongside significant top-line growth exceeding mid-teens revenue targets and a pathway to normalized margins of 7-10% by 2026. Furthermore, Evolent’s market leadership in specialty-focused value-based care, coupled with enhanced actuarial capabilities and data connectivity through partnerships, positions the company favorably for outsized growth in the coming years.

Evolent Health's financial outlook appears negative primarily due to a projected decline in revenue, citing a loss of approximately $100 million from the legacy Performance Suite segment as clients rationalize and exit markets. Despite anticipated reductions in general and administrative expenses driven by efficiency initiatives, the company is still expected to report only $20 million in EBITDA for the first quarter, with sequential performance for Q2 expected to remain flat. Additionally, the downward revision of earnings per share estimates for fiscal years 2026 and 2027, along with a reduced price target, further underscores the challenges facing the company.